Tonix Pharmaceuticals Holding Corp. TNXP revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Tonix Pharmaceuticals Holding Corp. reported revenue across 3 products and services; the largest, Zembrace Symtouch, was $9.31M, 71.1% of the filed sum (+9.0% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Zembrace Symtouch$9.31M71.1%+9.0% yoy
- Tosymra$2.37M18.1%+53.2% yoy
- Tonmya$1.42M10.8%no prior
Members sum to the consolidated $13.1M for this period.
- Tonmya$3.73M54.2%no prior
- Zembrace Symtouch$2.93M42.6%+44.6% yoy
- Tosymra$217K3.2%-46.2% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.